Glucagon (19-29), Human Mechanisms, Clinical Applications, a

Glucagon (19-29), Human: Mechanisms, Clinical Applications, and Research Perspectives
Introduction [Related: Sulfo-NHS-LC-Biotin]
Glucagon (19-29), human, is a synthetic peptide fragment corresponding to amino acids 19 through 29 of the full-length human glucagon molecule. Glucagon itself is a 29-amino acid peptide hormone produced by the alpha cells of the pancreas, primarily involved in glucose homeostasis through its actions on hepatic glucose production. The (19-29) fragment, also known as miniglucagon, has garnered significant interest due to its distinct biological activities compared to the full-length hormone, including its potential as a modulator of glucagon receptor signaling and its emerging roles in metabolic and neurological research (Unson et al., 1996, J Biol Chem). Mechanistically, Glucagon (19-29) acts as a partial agonist or antagonist at the glucagon receptor (GCGR), depending on the context and tissue type. Unlike the parent hormone, which robustly stimulates hepatic gluconeogenesis and glycogenolysis, the (19-29) fragment can inhibit or modulate these effects, suggesting a regulatory role in glucagon signaling pathways (Unson et al., 1996). This property positions Glucagon (19-29) as a valuable research tool for dissecting the physiological and pathophysiological roles of glucagon and its receptor, as well as a potential therapeutic candidate for metabolic disorders. [Related: chir-99021]
Clinical Value and Applications [Related: buy suramin online]
The clinical value of Glucagon (19-29), human, lies primarily in its ability to modulate glucagon receptor activity, offering a unique approach to the management of metabolic diseases such as diabetes mellitus and obesity. In contrast to full-length glucagon, which raises blood glucose levels, the (19-29) fragment has been shown to antagonize glucagon-induced hyperglycemia in animal models (Unson et al., 1996; Dalle et al., 2017, Peptides). This antagonistic property is particularly relevant in the context of type 2 diabetes, where hyperglucagonemia contributes to excessive hepatic glucose output and poor glycemic control. Furthermore, Glucagon (19-29) has demonstrated potential neuroprotective and neuromodulatory effects. Recent studies suggest that glucagon fragments, including (19-29), may influence synaptic transmission and neuronal excitability, opening avenues for research in neurodegenerative diseases and cognitive disorders (Dalle et al., 2017). Additionally, the peptide's stability and resistance to enzymatic degradation make it an attractive candidate for in vivo studies and therapeutic development. In summary, Glucagon (19-29), human, serves as a versatile tool in both basic and translational research, with applications spanning metabolic regulation, receptor pharmacology, and neuroscience.
Key Challenges and Pain Points Addressed
Current treatments for diabetes and metabolic syndrome often target insulin secretion or sensitivity, with limited options for directly modulating glucagon action. Hyperglucagonemia remains a significant challenge in the management of type 2 diabetes, contributing to persistent hyperglycemia despite optimal insulin therapy (Unger & Cherrington, 2012, Diabetes). Traditional glucagon receptor antagonists have shown efficacy in lowering blood glucose but are frequently associated with adverse effects, including elevated liver enzymes and dyslipidemia (Kazda et al., 2016, Diabetes Obes Metab). Glucagon (19-29) addresses several of these pain points by offering a more selective and potentially safer approach to glucagon receptor modulation. Its partial agonist/antagonist activity allows for fine-tuning of glucagon signaling without complete receptor blockade, potentially reducing the risk of side effects associated with full antagonists. Moreover, its peptide nature and structural similarity to endogenous glucagon minimize immunogenicity and off-target effects. Another challenge in glucagon research is the lack of specific tools to dissect the roles of different glucagon fragments and their receptors in various tissues. Glucagon (19-29), human, provides a well-characterized, synthetic peptide for in vitro and in vivo studies, facilitating the exploration of glucagon biology beyond glucose metabolism, including its roles in lipid metabolism, appetite regulation, and central nervous system function.
Literature Review
A growing body of literature supports the unique biological activities and research utility of Glucagon (19-29), human. Key studies include:
1. **Unson et al. (1996, J Biol Chem)**: This seminal study characterized the binding and activity of glucagon fragments, including (19-29), at the glucagon receptor. The authors demonstrated that Glucagon (19-29) acts as a competitive antagonist, inhibiting glucagon-induced cAMP accumulation in hepatocytes.
2. **Dalle et al. (2017, Peptides)**: This review summarized the physiological and pharmacological properties of glucagon fragments, highlighting the antagonistic effects of (19-29) on glucagon receptor signaling and its potential therapeutic implications in diabetes.
3. **Kazda et al. (2016, Diabetes Obes Metab)**: This clinical trial evaluated small molecule glucagon receptor antagonists in type 2 diabetes, underscoring the need for alternative approaches such as peptide-based modulators to mitigate adverse effects.
4. **Unger & Cherrington (2012, Diabetes)**: This review discussed the pathophysiological role of hyperglucagonemia in diabetes and the limitations of current therapies, providing context for the development of novel glucagon receptor modulators.
5. **Holst et al. (2011, Diabetes Obes Metab)**: The authors explored the role of glucagon and its fragments in metabolic regulation, emphasizing the therapeutic potential of targeting glucagon signaling in obesity and diabetes.
6. **Gelling et al. (2003, Nature)**: This study used glucagon receptor knockout mice to elucidate the physiological consequences of disrupted glucagon signaling, supporting the rationale for selective modulation using peptide fragments.
7. **Sloop et al. (2004, Endocrinology)**: The authors investigated the metabolic effects of glucagon receptor antagonism, providing a framework for evaluating the efficacy and safety of Glucagon (19-29) in preclinical models.
Experimental Data and Results
Experimental studies have elucidated the pharmacological properties of Glucagon (19-29), human, in both in vitro and in vivo systems. Unson et al. (1996) demonstrated that Glucagon (19-29) binds to the glucagon receptor with moderate affinity and inhibits glucagon-induced cAMP production in isolated rat hepatocytes. Dose-response experiments revealed that the (19-29) fragment could reduce cAMP accumulation by up to 60% at micromolar concentrations, indicating effective antagonism. In vivo, administration of Glucagon (19-29) in rodent models resulted in attenuation of glucagon-induced hyperglycemia without significant hypoglycemia or adverse effects on liver function (Dalle et al., 2017). These findings suggest that the peptide can selectively modulate hepatic glucose output, supporting its potential as a therapeutic agent or research tool. Additional studies have explored the stability and pharmacokinetics of Glucagon (19-29), revealing enhanced resistance to proteolytic degradation compared to full-length glucagon (Dalle et al., 2017). This property facilitates its use in prolonged in vitro assays and in vivo experiments, enabling detailed investigation of glucagon receptor dynamics and downstream signaling pathways. Neuroscientific research has also begun to investigate the effects of Glucagon (19-29) on neuronal activity. Preliminary data indicate that the peptide can modulate synaptic transmission and neuronal excitability in hippocampal slices, although the underlying mechanisms remain to be fully elucidated (Dalle et al., 2017).
Usage Guidelines and Best Practices
For research applications, Glucagon (19-29), human, is typically supplied as a lyophilized powder, which should be reconstituted in sterile water or appropriate buffer to the desired concentration. Stock solutions can be aliquoted and stored at -20°C to -80°C to maintain stability and prevent repeated freeze-thaw cycles. In vitro studies commonly employ concentrations ranging from 0.1 to 10 μM, depending on the assay and cell type. It is recommended to include appropriate controls, such as full-length glucagon and vehicle, to assess specificity and efficacy. For receptor binding and signaling assays, radioligand displacement or cAMP accumulation measurements are standard approaches. In vivo experiments should adhere to established animal welfare guidelines and employ dose-escalation studies to determine the optimal therapeutic window. Typical dosing regimens in rodent models range from 0.1 to 1 mg/kg, administered via intraperitoneal or intravenous injection (Unson et al., 1996; Dalle et al., 2017). Pharmacokinetic and pharmacodynamic parameters should be monitored, including blood glucose, hepatic enzyme levels, and potential off-target effects. Researchers are advised to validate the purity and identity of the peptide using analytical techniques such as HPLC and mass spectrometry, particularly when synthesizing or modifying the peptide in-house. Batch-to-batch consistency should be confirmed to ensure reproducibility of experimental results.
Future Research Directions
Despite significant progress, several questions remain regarding the physiological and therapeutic roles of Glucagon (19-29), human. Future research should focus on:
1. **Mechanistic Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 38 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11559224